Skip to main content
Log in

Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Pulmonary arterial hypertension (PAH) is a devastating complication of systemic lupus erythematosus (SLE). We aim to estimate the putative predictors contributing to early identification of PAH, thus improve appropriate medical intervention and a better prognosis. A retrospective case–control study was conducted. Forty-one SLE patients with PAH and 106 SLE patients without PAH were enrolled. Demographic variables, clinical features, and laboratory data were compared between the two groups. Univariate and multivariate logistic regression models were used to examine the predictors contributing to PAH in SLE. Serositis, Raynaud’s phenomenon, high disease activity, anticardiolipin antibodies, and anti-U1RNP were significantly associated with SLE-PAH. Univariate and multivariate analysis showed that Raynaud’s phenomenon, anticardiolipin antibodies, and anti-U1RNP were independent predictors of PAH in SLE. This study highlighted the clinical pattern of SLE-PAH patients, and underlined the leading predictors of PAH development among patients with SLE. Routine echocardiography is recommended in SLE patients with the independent predictors mentioned above.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G et al (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43(Suppl S):5S–12S

    Article  PubMed  Google Scholar 

  2. Tanoue LT (2003) Pulmonary hypertension in the collagen vascular diseases. Semin Respir Crit Care Med 24:287–296

    Article  PubMed  Google Scholar 

  3. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173:1023–1030

    Article  PubMed  Google Scholar 

  4. Li EK, Tam LS (1999) Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 26:1923–1929

    PubMed  CAS  Google Scholar 

  5. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al (1987) Primary pulmonary hypertension. A national propective study. Ann Intern Med 107(2):216–223

    PubMed  CAS  Google Scholar 

  6. Koh ET, Lee P, Gladman DD, Abu-Shakra M (1996) Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35:989–993

    Article  PubMed  CAS  Google Scholar 

  7. Quismorio FP Jr, Sharma O, Koss M, Boylen T, Edmiston AW, Thrnton PJ et al (1984) Immunopathologic, clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 13(4):349–359

    Article  PubMed  Google Scholar 

  8. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch D, et al (2010) Characterization of connective tissue disease associated pulmonary arteraial hypertension from the reveal registry: identifying system sclerosis as a unique phenotype. Chest 138(6):1383–1394

    Google Scholar 

  9. Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O et al (2008) Immunosuppressive therapy in lupus-and mixed connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 58(2):521–531

    Article  PubMed  Google Scholar 

  10. Hochberg MC (1997) For the diagnostic and therapeutic criteria committee of the American college of rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725

    Article  PubMed  CAS  Google Scholar 

  11. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al (1987) Primary pulmonary hypertension, A national prospective study. Ann Intern Med 107:216–233

    PubMed  CAS  Google Scholar 

  12. Galie N, Torbicki A, Barst R et al (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology. Eur Heart J 25(24):2243–2278

    Article  PubMed  Google Scholar 

  13. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H et al (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43(Suppl S):40S–47S

    Article  PubMed  Google Scholar 

  14. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M (2006) Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 130:182–189

    Article  PubMed  CAS  Google Scholar 

  15. Hachulla E, Gresin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide propective multicenter study. Arthritis Rheum 52(12):3792–3800

    Article  PubMed  Google Scholar 

  16. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F et al (2009) Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179(2):151–157

    Article  PubMed  Google Scholar 

  17. Chung SM, Lee CK, Lee EY, Yoo B, Lee SD, Moon HB (2006) Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 25:866–872

    Article  PubMed  Google Scholar 

  18. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N (2002) Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 29:282–287

    PubMed  Google Scholar 

  19. Guillevin L (2009) Vasculopathy and pulmonary arterial hypertension. Rheumatology 48(Suppl 3):iii54–iii57

    Article  PubMed  Google Scholar 

  20. Wigley FM (1996) Raynaud’s phenomenon and other features of scleroderma, including pulmonary hypertension. Curr Opin Rheumatol 8:561–568

    Article  PubMed  CAS  Google Scholar 

  21. Cefle A, Inanc M, Sayarlioglu M, Kamali S, Gul A, Ocal L, et al (2011) Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 31(2):183–189

    Google Scholar 

  22. Kasparian A, Floros A, Gialafos E, Kanakis M, Tassiopoulos S, Kafasi N et al (2007) Raynaud’s phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus 16(7):505–508

    Article  PubMed  CAS  Google Scholar 

  23. Levien TL (2010) Advances in the treatment of Raynaud’s phenomenon. Vasc Health Risk Manag 24(6):167–177

    Article  Google Scholar 

  24. Haas C (2004) Pulmonary hypertension associated with systemic lupus erythematosus. Bull Acad Natl Med 188(6):985–997

    PubMed  Google Scholar 

  25. Assous N, Allanore Y, Batteux F, Meune C, Toulon P, Weill B et al (2005) Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 23(2):199–204

    PubMed  CAS  Google Scholar 

  26. Asherson RA, Cervera R (2007) Pulmonary hypertension, antiphospholipid antibodies and syndromes. Clin Rev Allergy Immunol 32(2):153–158

    Article  PubMed  Google Scholar 

  27. Grunig E, Ehlken N, Ch Nagel (2008) Anticoagulation in pulmonary arterial hypertension. Hamostaseologie 8(4):225–230

    Google Scholar 

  28. Nishimaki T, Aotsuka S, Kondo H, Yamamoto K, Takasaki Y, Sumiya M et al (1999) Immunological analysis of pulmonary hypertension in connective tissue disease. J Rheumatol 26(11):2357–2362

    PubMed  CAS  Google Scholar 

  29. Gussin HA, Ignat GP, Varga J, Teodorescu M (2001) Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 44(2):376–383

    Article  PubMed  CAS  Google Scholar 

  30. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T et al (2004) American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl):78S–92S

    Article  PubMed  Google Scholar 

  31. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36:239–243

    Article  PubMed  CAS  Google Scholar 

  32. Vachiery JL, Brimioulle S, Crasset V, Naeije R (1998) False-positive diagnosis of pulmonary hypertension by Doppler echocardiography. Eur Respir J 12:1476–1478

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Xiuyan Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lian, F., Chen, D., Wang, Y. et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int 32, 1727–1731 (2012). https://doi.org/10.1007/s00296-011-1880-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-1880-4

Keywords

Navigation